Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
暂无分享,去创建一个
H. Jim | M. Byrne | J. Chahoud | Youngchul Kim | B. Manley | S. Gilbert | Vidhu B. Joshi | J. Adashek | J. Chadha | Philippe E. Spiess | N. Mason | A. M. Schneider | Savan S Shah | Savan Shah
[1] U. Capitanio,et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. , 2022, European urology.
[2] E. Philip,et al. Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review , 2021 .
[3] C. Porta,et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.
[4] C. Porta,et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.
[5] E. Arias,et al. United States Life Tables, 2018. , 2020, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[6] C. Porta,et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial , 2020, ESMO Open.
[7] T. Powles,et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.
[8] C. Kong,et al. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US , 2020, JAMA Network Open.
[9] Liangfang Shen,et al. Cost-effectiveness of pembrolizumab plus axitinib versus sunitinib as first-line therapy in advanced renal-cell carcinoma in the United States. , 2020, The oncologist.
[10] M. Atkins,et al. Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. , 2020, Immunotherapy.
[11] T. Choueiri,et al. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial , 2019, The oncologist.
[12] R. Motzer,et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[13] Q. Zhang,et al. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma , 2018, Journal of Immunotherapy for Cancer.
[14] K. Claxton,et al. Discounting in Economic Evaluations , 2018, PharmacoEconomics.
[15] M. Hoyle,et al. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England , 2018, PharmacoEconomics.
[16] Abe Dunn,et al. Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States , 2018, Health services research.
[17] M. Leshno,et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. , 2017, European urology.
[18] Liubao Peng,et al. Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and Chinese perspectives , 2017, Cancer.
[19] T. Choueiri,et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Culyer,et al. The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] T. Powles,et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[22] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[23] J. Larkin,et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.
[24] C. Mullins,et al. Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs? , 2014, Journal of managed care & specialty pharmacy.
[25] Á. Benedict,et al. Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population , 2013, ClinicoEconomics and outcomes research : CEOR.
[26] Yuting Zhang,et al. Comparing local and regional variation in health care spending. , 2012, The New England journal of medicine.
[27] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[28] Andrew H. Briggs,et al. Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.
[29] J. Angers,et al. The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data , 1998, PharmacoEconomics.
[30] W. Henley,et al. Improved curve fits to summary survival data: application to economic evaluation of health technologies , 2011, BMC Medical Research Methodology.
[31] Stephen M Roberts,et al. Body Weight Distributions for Risk Assessment , 2007, Risk analysis : an official publication of the Society for Risk Analysis.
[32] D. Posada,et al. Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests. , 2004, Systematic biology.